Takeda Pharmaceutical aims to generate up to $11 billion in peak revenue from three new drugs launching through next year. The Japanese drugmaker's stock price rose to an 8-year high on the news.
Takeda Pharmaceutical's new drug launches are expected to significantly boost its revenue, potentially impacting its market valuation and the broader pharmaceutical sector.
FOMC semi dovish. Alphabet and ServiceNow crater on earnings.home.saxoTrading stocks, CFDs, spread betting, futures, and options involves a high level of risk and may not be suitable for all investors. Prices can move rapidly, and losses can occur quickly and exceed your expectations.
Takeda Pharmaceutical aims to generate up to $11 billion in peak revenue from three drugs being launched in rapid succession as past growth investments bear fruit. The company's stock price rose to its highest level in more than 8 years on the news.
Pick the topics you care about. Get only what matters, on your cadence.